Coherus BioSciences, Inc. has announced a clinical collaboration with STORM Therapeutics, Ltd. to evaluate the safety and efficacy of a new drug combination in a Phase 1b/2 study. The study will assess STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor. This trial targets several types of cancer, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, and endometrial cancer. The Phase 2 portion of the study is set to evaluate expansion cohorts involving up to 188 patients in the United States. Under the agreement, Coherus will supply LOQTORZI, while STORM will serve as the trial sponsor. Both companies retain all commercial rights to their respective compounds.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.